Hong Kong stocks stand out | Canaoya-B (02162.HK) rose more than 5% during trading hours, launching phase III clinical trials of its first dual-target drug CM336.

According to the Securities Times app, Kangnaoya-B (02162.HK) rose more than 5% in mid-day trading, up 4.58% to HK$75.4 at the time of writing, with a turnover of HK$87.53 million.